Table 2.

Effects of potassium citrate therapy on topiramate‐induced hypocitraturia. Data show mean ± SD for urinary parameters related to urinary stone risk. Time points shown are from 24 h urine collections while on topiramate alone (dosage mean, 131 ± 111 mg; median, 100 mg day^–1) for 9.7 ± 4.1 months and from 24 h urine collections after adding potassium citrate (dosage mean, 58 ± 21 mEq day^–1; median, 60 mEq day^–1). P values for differences between urinary parameters are shown. ‡Significant differences (P ≤ 0.05) are in bold and denoted with an asterisk

	Topiramate alone	Topiramate plus potassium citrate	P value
Volume (l)	1.36 ± 0.55	1.89 ± 0.98	0.14
pH	6.65 ± 0.55	7.25 ± 0.78	*0.04
Calcium (mg)	138 ± 73	175 ± 81	0.23
Oxalate (mg)	33 ± 15	40 ± 24	0.37
Uric acid (mg)	492 ± 164	508 ± 151	0.81
Citrate (mg)	198 ± 120	408 ± 274	*0.04
Sodium (mEq)	131 ± 78	154 ± 38	0.28
Sulfate (mmol)	12 ± 6.7	13 ± 5.4	0.49
Phosphorus (mg)	643 ± 289	633 ± 224	0.92
Magnesium (mg)	89 ± 58	108 ± 68	0.46
Potassium (mEq)	47 ± 25	70 ± 44	0.08
Creatinine (mg)	1182 ± 311	1126 ± 355	0.68
CaOx SS†	2.16 ± 0.92	1.99 ± 1.6	0.76
Brushite SS	2.78 ± 1.4	2.99 ± 2.8	0.83

^†SS, relative supersaturation.

^‡Where data plots revealed unequal variance, a t‐test assuming unequal variance was used to assess statistical difference.